{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalMethod":"single-sample binomial test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.6","upperLimit":"63.2","value":"48.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"nCR plus CR rate after 8 cycles of therapy as defined by the modified European Society for Bone and Marrow Transplantation (EBMT) criteria per investigator assessment as the proportion of participants with nCR or CR as their best overall response.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): The Full analysis set (FAS) comprised of all subjects who took at least one dose of any study treatment component.","reportingStatus":"POSTED","timeFrame":"after 24 weeks (8 cycles; cycle = 21 days)","title":"Percentage of Participants With Near Complete Response (nCR)/ Complete Response (CR) Rate","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}